Epigenomics Reports Third Quarter 2022 Earnings
Epigenomics (ETR:ECX) Third Quarter 2022 Results
Key Financial Results
Net loss: €1.56m (down by 155% from €2.84m profit in 3Q 2021).
€0.10 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Epigenomics Earnings Insights
Looking ahead, revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany.
Performance of the German Biotechs industry.
The company's shares are up 17% from a week ago.
What about risks? Every company has them, and we've spotted 7 warning signs for Epigenomics (of which 5 make us uncomfortable!) you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here